Renamed Adheron cements focus on Cadherin-11 asset
By Jennifer Boggs
Friday, December 27, 2013
Back in 2006, a company named Synovex Corp. was launched around discoveries by scientists Michael Brenner and David Lee into the role of Cadherin-11 as an adhesive control part of cell-cell interaction. And for several years, the fully virtual discovery firm operated under the radar until a lead clinical asset emerged: an antibody designed to inhibit Cad-11 designated SDP051.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.